Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Estramustine”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 991 records · Page 55Linked to original sources
PubMed1995

Preoperative endocrine therapy in patients with locally advanced prostate cancer.

Recently, there has been increased interest in the application of preoperative endocrine therapy prior to radical prostatectomy for locally advanced cancer in order to enhance surgical curability and increase survival. Between 1986 and 1993, 40 patients with prostate cancer were given endocrine therapy before radical prostatectomy. Fifteen patients had stage B2 disease and 25 stage C. The median duration of preoperative endocrine therapy was 3.8 months, and all the patients subsequently underwent radical prostatectomy, pelvic lymphadenectomy and castration. There was an average 25.5% (0-71.8%) decreases in the maximal cross-sectional area of the prostate gland as determined by transrectal ultrasonography. Twenty-four of 25 patients with elevated levels of serum prostate-specific antigen (PSA) showed normal values after preoperative endocrine therapy. Evaluation of treatment-related histological effects, divided into three grades, revealed that 17 patients had pronounced, 11 moderate and 12 poor or no regression. Thirteen of the 40 patients (33%) demonstrated pathological downstaging of disease status from the diagnosis made at the initial clinical examination. After a median follow-up period of 36 months (3-100 months), 36 of the 40 patients are disease-free; two died of cancer 43 and 50 months after surgery, respectively. These results suggest that preoperative endocrine therapy may play an important role in the management of locally advanced prostatic cancer.

Adenocarcinoma↗
PubMed1995

[Estramustinphosphate in the treatment of prostatic cancer].

OBJECTIVES: This study describes our experience in the treatment of disseminated prostatic cancer with stramustine phosphate. METHODS: We reviewed our series of 41 patients with disseminated prostatic cancer; of these, 6 were treated with stramustine phosphate. Patient age, clinical features, tumor stage and diagnostic methods utilized were analyzed. All patients received 600 mg/day oral stramustine in two doses. RESULTS: All 6 patients treated with stramustine phosphate showed clinical improvement, the levels of tumor markers returned to normal and bone metastasis disappeared. Moreover, no side effects were observed. CONCLUSIONS: Further research is necessary on the effective use of stramustine phosphate and at the appropriate time in order to obtain the best results as there is no other alternative except radical surgery and at an early stage.

Aged↗
PubMedDate not supplied

Growth inhibitory effect of estrogen conjugated drugs against primary cultured breast cancer cells.

An in vitro assay method for predicting the hormonal response of primary cultured cells was used in 38 women with breast carcinoma. The response to 17 beta-estradiol (E2) was compared with other hormone treatments, such as tamoxifen (TAM), estracyt (EC) and bestrabucil (BB). The response to the E2-conjugated drugs (EC and BB) and TAM showed a good correlation with the response to E2 (p < 0.01). Coincidental rates of EC and BB response (stimulatory, insensitive, and inhibitory) with E2 response were 47% (16/34) and 53% (16/30) of cases, respectively. Cells showing an inhibitory response to E2 were also inhibited by EC and BB in 60% (6/10) and 100% (8/8) of cases, respectively. In premenopausal women, 28% (5/18) and 43% (6/14) of cases were inhibited by EC and BB, respectively, whereas in postmenopausal women 44% (7/16) and 56% (9/16) of cases showed inhibition with EC and BB, respectively. The inhibitory response to the E2-conjugated drugs was not significantly different between pre- and post-menopausal women. Cells resistant to inhibition by TAM were inhibited by EC and BB, respectively, in 17% (4/24) and 30% (6/20) of cases. These results indicate that E2-conjugated drugs may inhibit the growth of breast cancer cells and that their inhibitory actions might be different from those of TAM.

Adult↗
PubMed1976

Histochemical and ultrastructural study of prostatic tissue from baboons treated with antiprostatic drugs.

Histochemical and ultrastructural investigation of the prostate in baboons treated parenterally with saline revealed that the epithelial cells in the caudal prostatic lobe possess very high acid phosphatase activity, moderate nonspecific esterase activity and alkaline phosphatase activity, and little or no amino-peptidase or beta-glucuronidase activity. Only a few lipofuscin granules were found. Ultrastructurally, the epithelial cells had a characteristic polar appearance with a supranuclear zone dominated by large secretory vacuoles. Secretory granules were abundant in the apical zone. No clear difference was found between the cranial and the caudal prostate except that the acid phosphatase activity of the epithelial cells was much lower in the former. In baboons treated with estraumustine phosphate, diethylstilbestrol diphosphate, or with flutamide, i.e., drugs used in the treatment of advanced prostatic carcinoma, the epithelial cells in the caudal prostatic lobe showed a varying degree of atrophy, which was least in the flutamide-treated animals. The histologic changes were accompanied by only minor changes in the enzyme activities, but the number of histochemically demonstrable lipofuscin granules were substantially increased, a finding confirmed by electron microscopy. The drugs did not notably affect the cranial prostate. The findings showed that the caudal, but not the cranial, lobe of the prostate of the baboon resembles the human prostate and can be affected by drugs known to have a desirable effect on the carcinomatous human prostate.

Acid Phosphatase↗
PubMed1993

[Urethral metastases of prostatic adenocarcinoma].

Although the penis is highly vascularized, secondary penile tumors are rare and 28% of these metastasize from prostatic tumors. Urethral metastases are uncommon and may be caused by seeding following manipulation of the prostate with instruments or spread directly from the adjacent structures. This condition can be controlled and treated effectively with first or second line hormone therapy. Herein we describe a 65-year-old male with disseminated prostatic adenocarcinoma who presented multiple urethral metastases that were successfully treated with stramustine phosphate.

Adenocarcinoma↗
PubMed1977

Effect of estracyt on the rat prostate.

Two types of experiments were performed to elucidate the estrogenic effect of estracyt on the ventral and immature rats that had received injections of testosterone; then changes in weight of accessory rats and changes in weight of the total body, the ventral and the dorsolateral prostates, and adrenal gland, and changes in activities of testosterone 5alpha-reductase, alkaline phosphatase, and arginase of both lobes of the prostates were examined. In the second experiment, estracyt was injected into castrates rats and immature rats that had received injections of testosterone; then changes in weight of accessory sex organs were determined. Because similar changes were induced by treatment of animals with estradiol-17beta, it was concluded that the effect of estracyt on the prostates was most likely attributable to the estrogenic effect of the drug.

3-Oxo-5-alpha-Steroid 4-Dehydrogenase↗
PubMed1996

Primary metastatic carcinoma of the prostate in younger men: a plea to think over usual therapeutic strategies.

METHOD: The time from first diagnosis of primary multiple metastatic prostate carcinoma until progression and until death in patients less than 60 years old under two different therapeutic regimens was evaluated. RESULTS: In the group with pure androgen deprivation (n = 21), the mean time until progression was 11.3 (6-55) months, the mean survival time being 21.4 (11-75) months. In the group with androgen deprivation plus cytostatic therapy (n = 10), progression was noted after 26.7 (15-77) months with a medium survival time of 26.2 (16-82) months. CONCLUSION: The data argue in favor of changing the usual treatment strategy to combination therapy in "young' patients with primary metastatic prostatic cancer.

Adult↗